Top alert for 2014: MYGN (50%), LIVE (45%), CTIC (115%), KOOL (88%), PZG (32%), GOLD (6%), IOC (6%), RSOL(18%), PLUG (70%), IMMU (26%)

Thursday, September 18, 2014

20 minutes of Day Trade for Sept 18th: TRP Short, AOL Short,GDOT Long, RAD Long, RPRX Long

Earning after market  close: 
ORCL (Implied earning move of 5%), RHT (implied earning move of 11%), TIBX (implied earning move of 8%)


All position are closed:

TRP Trade:
TRP Trade

TRP Short at 56.69 Close at 56.03

Shorted $AOL at $44.16

AOL Short: in at $43.01, and out at $42.60

90% of the stock s that pops drop, take short and then long
AOL


RPRX Long @ 9.78 closed at 10.05
RPRX 


VHC Long @ 4.48 and closed at $4.88


VHC Long: @4.72 closed at 4.84


RPRX Support
RPRX


RPRX Long @9.17, and out 9.45

RPRX Long @9.96 and out at 10.15



GDOT Long: 18.69 and closed at 19.24
GDOT 
RAD Long @ 5.80 out at 5.84



RAD Long:

Day Trade watchlist:
MCHX, LIVE, VVUS, AUXL, AVNR, RPRX, GDOT, RAD, ZGNX, FANG, VNET, MNDL

Only IPO today is PRQR

News that matter:

ConAgra beats by $0.04, reports revs in-line; reaffirms FY15 EPS guidance; sees Q2 EPS comparable to last year (CAG)

Salix Pharma announces Cipla has granted Salix exclusive rights under certain patent applications in the 'Rifaximin Complexes' patent family controlled by Cipla (SLXP) 

 USEC Inc. expects to complete the final steps necessary to emerge from its Chapter 11 restructuring on September 30, 2014, under the name Centrus Energy Corp.; co's new common stock shares are expected to begin trading on the New York Stock Exchange under the ticker symbol 'LEU' on that date. (USU) 

Rite Aid beats by $0.07, reports revs in-line; lowers FY15 EPS, rev guidance, narrows comp guidance (RAD) 

Auxilium Pharma presents XIAFLEX (:CCH) data from MULTICORD and retreatment studies at the ASSH Annual Meeting; data support CCH could be used to treat two affected joints concurrently; positive results presented from additional studies evaluating CCH retreatment for recurrent contracture (AUXL)

 IHS beats by $0.05, reports revs in-line; narrows FY14 EPS guidance; raises FY14 revenue guidance (IHS)


 Vivus and Auxilium (AUXL) announce FDA approval of STENDRA sNDA (VVUS)

No comments:

Post a Comment